BioWorld

April 12, 2010

View Archived Issues

Common Denominator of Cardiac, Vascular Disease

Read More

Biogen, Gilead, Others Warned About Misleading Promotions

Read More

Other News To Note

Read More

Stock Movers

Read More

Financings Roundup

Read More

Clinic Roundup

Read More

U.S. Patent Disclosures

Read More

Bench Press

Read More

Tengion Prices $30M IPO Despite Early Stage, High-Risk Programs

Tengion Inc., which priced a $30 million initial public offering on Friday, was easily the earliest-stage biotech to try its luck in the current IPO window. (BioWorld Today) Read More

FDA Rejects CTI Lymphoma Drug; Firm to Seek Compassionate Use

Read More